Lantern Pharma Inc.
LTRN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001763950
No open-market purchases or sales by Lantern Pharma Inc. insiders were filed in the last 90 days; 39 institutions reported holding it in 13F filings for Q2 2026, worth $12.0M in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in Lantern Pharma Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- −2 vs. Q4 2022
- Shares held
- 1.08M
- +17.2K (+1.6%) vs. Q4 2022
- Total value
- $5.23M
- −$163.0K (−3.0%) vs. Q4 2022
- New holders
- 4
- 5 more added
- Sold out
- 6
- 6 more reduced
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LTRN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 39 | $12.0M |
| Q1 2026 | 33 | $2.87M |
| Q4 2025 | 33 | $6.91M |
| Q3 2025 | 30 | $9.89M |
| Q2 2025 | 35 | $7.11M |
| Q1 2025 | 32 | $8.62M |
| Q4 2024 | 32 | $8.00M |
| Q3 2024 | 31 | $4.90M |
| Q2 2024 | 39 | $6.01M |
| Q1 2024 | 34 | $9.75M |
| Q4 2023 | 30 | $4.94M |
| Q3 2023 | 27 | $3.93M |
| Q2 2023 | 25 | $6.50M |
| Q1 2023 | 21 | $5.23M |
| Q4 2022 | 23 | $5.40M |
| Q3 2022 | 26 | $6.84M |
| Q2 2022 | 26 | $8.06M |
| Q1 2022 | 25 | $10.4M |
| Q4 2021 | 33 | $13.1M |
| Q3 2021 | 25 | $15.7M |
| Q2 2021 | 22 | $19.7M |
| Q1 2021 | 24 | $25.5M |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Lantern Pharma Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Allworth Financial LP | 100 | $483 | 0.00% | +100 | New |
| Cranbrook Wealth Management, LLC | 717 | $3.46K | 0.00% | +717 | New |
| Tower Research Capital LLC (TRC) | 2,117 | $10.0K | 0.00% | +2,089+7,460.7% | Added |
| Wells Fargo & Company | 4,486 | $21.7K | 0.00% | +501+12.6% | Added |
| Citadel Advisors LLC | 10,976 | $53.0K | 0.00% | −8,345−43.2% | Reduced |
| Northern Trust Corp | 12,629 | $61.0K | 0.00% | 00.0% | Unchanged |
| Sigma Planning Corp | 17,275 | $83.4K | 0.00% | −25−0.1% | Reduced |
| Commonwealth Equity Services, LLC | 20,186 | $97.0K | 0.00% | +20,186 | New |
| BlackRock Inc. | 21,450 | $103.6K | 0.00% | +558+2.7% | Added |
| Renaissance Technologies LLC | 24,600 | $119.0K | 0.00% | +3,500+16.6% | Added |
| Wolff Wiese Magana LLC | 26,478 | $127.9K | 0.10% | −620−2.3% | Reduced |
| Bank of New York Mellon Corp | 26,480 | $127.9K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 27,000 | $130.4K | 0.00% | +12,159+81.9% | Added |
| State Street Corp | 27,752 | $134.0K | 0.00% | 00.0% | Unchanged |
| Horizon Kinetics Asset Management LLC | 30,000 | $144.9K | 0.00% | +30,000 | New |
| Redmond Asset Management, LLC | 49,189 | $237.6K | 0.08% | −1,184−2.4% | Reduced |
| Geode Capital Management, LLC | 57,774 | $279.0K | 0.00% | 00.0% | Unchanged |
| CM Management, LLC | 60,000 | $290.0K | 0.34% | 00.0% | Unchanged |
| Carlson Capital L P | 124,900 | $603.3K | 0.06% | −13,100−9.5% | Reduced |
| GWM Advisors LLC | 172,115 | $831.3K | 0.01% | −723−0.4% | Reduced |
| Vanguard Group Inc | 367,454 | $1.77M | 0.00% | 00.0% | Unchanged |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −15,134−100.0% | Sold out |
| Lynwood Capital Management Inc. | 0 | $0 | 0.00% | −12,000−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −864−100.0% | Sold out |
| Steward Partners Investment Advisory, LLC | 0 | $0 | 0.00% | −300−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −289−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −8−100.0% | Sold out |